de Bruyn, Magali
Breynaert, Christine
Arijs, Ingrid
De Hertogh, Gert
Geboes, Karel
Thijs, Greet
Matteoli, Gianluca
Hu, Jialiang
Van Damme, Jo
Arnold, Bernd
Ferrante, Marc
Vermeire, Séverine
Van Assche, Gert
Opdenakker, Ghislain
Article History
Received: 12 July 2016
Accepted: 24 March 2017
First Online: 31 May 2017
Competing interests
: G.V.A. provided financial support for research from Abbvie and Ferring; lecture fee(s) from Janssen-Cilag, Merck, Abbvie and consultancy for PDL BioPharma, UCB Pharma, Sanofi-Aventis, Abbvie, Ferring, Novartis, Biogen Idec, Janssen Biologics, NovoNordisk, Zealand Pharma A/S, Millenium/Takeda, Shire, Novartis and BMS; S.V. provided grant support, lecture fees and consulting fees from Abbvie, Centocor, MSD, Takeda, Pfizer, Shire, Tillotts Pharma, Hospira, Munipharma and Genentech/Roche; M.F. reports fees from MSD, Janssen, Abbvie, Ferring, Chiesi, Tillotts and Zeria. G.D.H. received consultancy fees from Genentech, Centocor and Galapagos. The remaining authors declare no conflict of financial interests.